NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it will postpone the company update previously scheduled for Friday, October 20, 2023, due to important developments impacting the timing of the event.
瑞士苏黎世 /ACCESSWIRE /2023 年 10 月 19 日/ 专注于为罕见和复杂中枢神经系统疾病患者发现和开发创新疗法的瑞士临床阶段生物制药公司NLS Pharmacetics Ltd.（纳斯达克股票代码：NLSP，NLSPW）（“NLS” 或 “公司”）今天宣布，由于重要进展影响了活动时间，它将推迟原定于2023年10月20日星期五发布的公司更新。
About NLS Pharmaceutics Ltd.
关于 NLS 制药有限公司
NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS Pharmaceutics Ltd.（纳斯达克股票代码：NLSP）是一家处于开发阶段的全球生物制药公司，与世界一流的合作伙伴和国际知名的科学家网络合作，专注于为医疗需求未得到满足的罕见和复杂中枢神经系统疾病患者发现和开发创新疗法。NLS总部位于瑞士，成立于2015年，由一支经验丰富的管理团队领导，他们在开发和商业化候选产品方面有着良好的记录。欲了解更多信息，请访问。
For additional information:
欲了解更多信息：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
ml@nls-pharma.com
玛丽安·兰伯森（投资者和媒体）
NLS 制药有限公司
ml@nls-pharma.com
SOURCE: NLS Pharmaceutics AG
来源： NLS 制药股份公司